Please use this identifier to cite or link to this item: http://buratest.brunel.ac.uk/handle/2438/11037
Title: Regulation of indoleamine 2,3-dioxygenase in primary human saphenous vein endothelial cells.
Authors: Mouratidis, PX
George, AJ
Keywords: HSVEC;IFNγ;VEGFβ;Endothelium;Inflammation
Issue Date: 2015
Publisher: Dove Press Ltd
Citation: Journal of Inflammation Research, 2015: 8, 97–106, (21 May 2015)
Abstract: BACKGROUND: Indoleamine 2,3-dioxygenase (IDO) is an enzyme associated with the regulation of immune responses. Cytokines such as IFNγ induce its expression in endothelial cells originating from immune-privileged sites. In this study, we investigate regulators of IDO in primary endothelial cells from a non-immune-privileged site and determine whether IDO expression affects immune cell behavior. METHODS: IDO expression was determined using real-time quantitative polymerase chain reaction and immunoblotting. IDO activity was estimated using an IDO enzyme assay. Primary cells were transfected using microporation, and T-cell migration was determined using a cell transmigration assay. RESULTS: IDO is expressed in human saphenous vein endothelial cells after stimulation with IFNγ but not after treatment with TNFα, IL-1β, IL-2, IL-4, IL-6, or IL-10. VEGFβ and heparin negatively regulate IFNγ-driven increases in IDO. Overexpression of IDO in endothelial cells does not affect transmigration of T-cells. CONCLUSION: IDO is expressed in human saphenous vein endothelial cells after stimulation with IFNγ. Heparin and angiogenesis stimulators such as VEGFβ negatively regulate its expression.
URI: http://www.dovepress.com/regulation-of-indoleamine-23-dioxygenase-in-primary-human-saphenous-ve-peer-reviewed-article-JIR
http://bura.brunel.ac.uk/handle/2438/11037
DOI: http://dx.doi.org/10.2147/JIR.S82202
ISSN: 1178-7031
Appears in Collections:Dept of Clinical Sciences Research Papers

Files in This Item:
File Description SizeFormat 
Fulltext.pdf756.16 kBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.